Polysaccharide A - Symbiotix Biotherapies

Drug Profile

Polysaccharide A - Symbiotix Biotherapies

Alternative Names: PSA - Symbiotix Biotherapies; Reglemers™; SYMB 104; ZPS therapeutic - Symbiotix; Zwitterionic polysaccharide - Symbiotix

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Symbiotix Biotherapies
  • Developer Geisel School of Medicine; Symbiotix Biotherapies
  • Class Antibacterials; Polysaccharides
  • Mechanism of Action CD4-positive T-lymphocyte modulators; Immunomodulators; Interleukin-10 expression stimulants; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Inflammatory bowel diseases; Multiple sclerosis

Most Recent Events

  • 01 Nov 2017 Symbiotix Biotherapies has patents pending for polysaccharide A (Reglemers) in USA
  • 17 Feb 2017 Symbiotix Biotherapies has patent protection for SYMB 104 in USA
  • 20 Sep 2016 Symbiotix Biotherapies receives Small Business Technology Transfer (STTR) Program award from the National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for polysaccharide A development in Inflammatory bowel disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top